Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07225556
PHASE1

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Official title: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2025-11-18

Completion Date

2026-12

Last Updated

2026-03-09

Healthy Volunteers

Yes

Interventions

DRUG

LY4167586

Administered SC

DRUG

Placebo

Administered SC

DRUG

LY4167586

Administered IV

Locations (2)

Fortrea Clinical Research Unit

Madison, Wisconsin, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore